Skip to main content
Retour
AVBP logo

ArriVent BioPharma, Inc. Common Stock

Qualité des données : 100%
AVBP
NASDAQ Healthcare Biotechnology
22,75 €
▲ 0,80 € (3,64%)
Cap. Boursière : 1,01B
Fourchette du Jour
22,34 € 22,98 €
Fourchette 52 Semaines
15,47 € 27,22 €
Volume
232 221
Moyenne 50J / 200J
22,89 € / 21,19 €
Clôture Précédente
21,95 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -6,1 0,3
P/B 3,3 3,0
ROE % -58,9 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
44,00 € +93.4%
Low: 43,00 € High: 45,00 €
BPA Prévisionnel
-3,76 €
CA Est.
125 000,0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 3,55 €
1,66 € – 5,62 €
433,92M 5
FY2029 0,84 €
0,39 € – 1,34 €
266,77M 2
FY2028 -1,47 €
-3,61 € – 1,91 €
130,96M 7

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -160,59M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-58,88%
ROIC-43,34%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,00
Current Ratio12,83
Interest Coverage0,00

Valorisation

P/E Ratio
-6,05
Forward P/EN/A
P/B Ratio3,27
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -166,31M
ROE -58,88% ROA -49,92%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -160,59M
ROIC -43,34% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 12,83
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6,05 Forward P/E N/A
P/B Ratio 3,27 P/S Ratio N/A
PEG Ratio -0,07 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 8044,70 Fwd Earnings Yield N/A
FCF Yield -15,97%
Market Cap 1,01B Enterprise Value 960,06M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -166,31M -80,49M -69,33M -36,91M -51,61M
EPS (Diluted) -4,32 -2,56 -2,17 -1,10 -40,44
Gross Profit 0,0 0,0 0,0 0,0 0,0
Operating Income -177,53M -94,31M -74,59M -36,91M -8,70M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 333,17M 274,94M 163,10M 182,83M 43,04M
Total Liabilities 25,95M 17,29M 11,80M 8,37M 1,82M
Shareholders' Equity 307,22M 257,65M 151,30M 174,46M 41,22M
Total Debt 14 000,0 176 000,0 317 000,0 139 000,0 0,0
Cash & Equivalents 45,54M 74,29M 150,39M 163,37M 37,28M
Current Assets 332,90M 226,98M 159,97M 182,62M 42,95M
Current Liabilities 25,95M 17,27M 11,62M 8,36M 1,82M